Alx Oncology Holdings (ALXO) Cash & Equivalents (2019 - 2026)

Alx Oncology Holdings has disclosed Cash & Equivalents across 8 years of filings, most recently posting $32.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $32.3 million, up 56.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.3 million (up 56.61% YoY), and the FY2025 annual result was $16.4 million, down 6.8% from the prior year.
• Cash & Equivalents came in at $32.3 million for Q1 2026 at Alx Oncology Holdings, up from $16.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $159.1 million in Q1 2022 to a low of $14.0 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $22.4 million (2023), against an average of $37.8 million.
• Across the five-year window, Cash & Equivalents plunged 87.26% in 2022 and jumped 56.61% in 2026, its largest moves.
• Alx Oncology Holdings' Cash & Equivalents stood at $48.8 million in 2022, then slumped by 54.11% to $22.4 million in 2023, then dropped by 21.6% to $17.6 million in 2024, then slipped by 6.8% to $16.4 million in 2025, then surged by 97.18% to $32.3 million in 2026.
• The last three Cash & Equivalents figures came in at $32.3 million (Q1 2026), $16.4 million (Q4 2025), and $23.4 million (Q3 2025), per Business Quant data.